CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $54.74, moving -2.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%.

CRISPR is one of the most revolutionary technologies of the modern era, and now it's being used to bring back long-lost genes ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of more ...

Study finds CRISPR/Cas gene editing causes “chromatin fatigue” – another surprise mechanism by which it can produce unwanted ...

Scientists have successfully used DNA base editing to treat the previously incurable T-cell acute lymphoblastic leukaemia, marking a significant medical breakthrough.

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...